Vol 7: Switching patients from other inhaled corticosteroid devices to the Easyhaler®: historical, matched-cohort study of real-life asthma patients.Reportar como inadecuado



 Vol 7: Switching patients from other inhaled corticosteroid devices to the Easyhaler®: historical, matched-cohort study of real-life asthma patients.


Vol 7: Switching patients from other inhaled corticosteroid devices to the Easyhaler®: historical, matched-cohort study of real-life asthma patients. - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Descargar gratis o leer online en formato PDF el libro: Vol 7: Switching patients from other inhaled corticosteroid devices to the Easyhaler®: historical, matched-cohort study of real-life asthma patients.
This article is from Journal of Asthma and Allergy, volume 7.AbstractPurpose: To investigate the clinical and cost effectiveness of switching real-life asthma patients from other types of inhalers to the Easyhaler® EH for the administration of inhaled corticosteroids ICS. Patients and methods: Historical, matched-cohort study of 1,958 asthma patients children and adults treated in UK primary-care practices, using data obtained from the Optimum Patient Care Research Database and Clinical Practice Research Datalink. Other inhalers OH included pressurized metered-dose inhalers, breath-actuated inhalers, and dry-powder inhalers, delivering beclomethasone, budesonide, fluticasone, or ciclesonide. Patients remaining on OH unchanged same drug, dosage, and device; n=979 were matched 1:1 with those switched to the EH beclomethasone or budesonide at the same or lower ICS dosage n=979, based on age, sex, year of index patient review-switch, most recent ICS drug, dosage, and device, and the number of severe exacerbations and average daily short-acting β2 agonist SABA dosage in the preceding year. Clinical outcomes and health care costs were compared between groups for 12 months before and after the switch. Co-primary clinical outcomes were: 1 risk domain asthma control RDAC – no asthma-related hospitalization, acute oral steroid use, or lower respiratory tract infection LRTI; 2 exacerbation rate American Thoracic Society ATS definition – where exacerbation is asthma-related hospitalization or acute oral steroid use; 3 exacerbation rate clinical definition – where exacerbation is ATS exacerbation or LRTI; and 4 overall asthma control OAC – RDAC plus average salbutamol-equivalent SABA dosage ≤200 μg-day. Non-inferiority at least equivalence of EH was tested against OH for the four co-primary outcomes in order hierarchical approach by comparing the difference in proportions of patients EH-OH achieving asthma control or having no exacerbations in the outcome year, using a limit of 10% difference. Results: Non-inferiority was shown for the EH for all four co-primary outcomes. There were no significant differences between groups for RDAC or exacerbation rates, but EH patients were significantly more likely to achieve OAC adjusted odds ratio 95% confidence interval: 1.26 1.05, 1.52, as significantly more EH than OH patients had an average SABA dosage of ≤200 μg-day 52% versus 47%, respectively; P



Autor: Price, David; Thomas, Vicky; von Ziegenweidt, Julie; Gould, Shuna; Hutton, Catherine; King, Christine

Fuente: https://archive.org/



DESCARGAR PDF




Documentos relacionados